Shyamasundaran Kottilil, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

University Of Maryland School Of Medicine - Baltimore MD
Rank: Full Professor
Years: 2014

None Reported

Interleukin-15 Induced peripheral immune activation is associated with Hepatic Stellate Cell activation in HIV/HCV co-infected individuals.
J Infect Dis
200: 619-23
Date: 12 2008

Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to Mapatumumab-induced apoptosis.
Hepatol Research
39:1178-89
Date: 02 2009

HIV and HCV infections induce distinct immunologic imprints with implications for the pathogenesis of liver disease and therapeutic response to interferon-alpha.
Hepatology
50: 34-45
Date: 05 2009

Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection.
AIDS Res Hum Retr
10:1029-37
Date: 06 2009

Hepatitis C viral kinetics during treatment with Peg-IFN-alpha 2b in HIV/HCV co-infected patients as a function of baseline CD4+T cell counts.
J AIDS
52: 452-8
Date: 10 2009

Therapeutic response to Peg-IFN_alpha-2b and ribavirin in HIV/HCV co-infected African American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
AIDS
23:2439-50
Date: 11 2009

HIV/HCV co-infected virologic responders to pegylated interferon and ribavirin therapy more frequently incur IFN-related adverse events than non-responders.
J AIDS
53: 357-63
Date: 03 2010

The Interferon stimulated gene 15 is a proviral factor for the Hepatitis C virus and an attenuator of the IFN response.
Gut
59:1111-9
Date: 07 2010

Impact of Interferon Ribavirin treatment on Hepatitis C Virus protease quasipecies diversity in HIV/HCV co-infected patients.
J Infect Dis
202:889-93
Date: 11 2010

Proteome wide anti-HCV and anti-HIV profiling for predicting and monitoring response to HCV treatment in HIV co-infected patients.
J Infect Dis
202: 894-8
Date: 11 2010